Skip to main content
CTRECareTrust REIT, Inc.Sell5.2·$39.43
CTRE · Decision

Should you buy CareTrust REIT (CTRE)?

Updated

A healthcare REIT with genuinely exceptional quality — 9/9 Piotroski F-Score, 64% margins, and free cash flow at 288% of net income — is overshadowed by four consecutive earnings misses, weak single-digit growth, a dividend yield safety warning, and heavy bearish options positioning (put/call ratio of 2.44), leaving the overall setup cautious despite strong analyst conviction and oversold technicals.

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Verdict
SELL
Score
5.2/10
Price
$39.43
Entry / Take Profit (TP) / Stop Loss (SL)
/ $39.42 / $37.29

Engine methodology range

Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.

What the engine is tracking

Analysts see 23% upside to the consensus target from the current price, and recent news sentiment is positive — reflecting research community confidence in the business despite near-term earnings noise.

Stable
Sentiment
Expectation
Analyst targets hold and price gradually closes the gap toward the 23% upside over the next 12 months.

CounterThe near-term take-profit level is only 6.7% above the current price, meaning the risk/reward at the next resistance level remains thin even if the longer-term analyst target is compelling.

The business generates free cash flow equal to 288% of net income, posts 64% margins, and holds a perfect Piotroski F-Score of 9/9, placing it among the best-in-class names in its peer group on quality metrics.

Stable
Quality
Expectation
Cash generation and margins remain near current levels, sustaining the quality designation over the next four quarters.

CounterDespite exceptional cash and quality metrics, four consecutive quarterly misses and a dividend yield safety warning indicate the payout may be at risk — an uncovered dividend would undermine the quality case for income-oriented investors.

The company has missed earnings estimates in all four of the most recent reported quarters, with the oldest miss at -15.7% and the most recent narrowing sharply to -1.3%, suggesting analysts are gradually resetting expectations toward actual results.

Stable
Earnings
Expectation
The miss streak ends with the next quarterly report as the narrowing trajectory reaches breakeven and the company delivers an in-line or better result.

CounterEven a four-quarter miss streak with narrowing gaps may persist if the business faces structural headwinds to meeting consensus targets, and each additional miss reinforces negative sentiment among institutional holders.

▸ Show 2 more pillars

RSI is near 20 (oversold), on-balance volume is rising (accumulation), and the stock remains above the 200-day moving average — a combination that creates a potential mean-reversion setup within an intact longer-term uptrend.

Stable
Momentum
Expectation
Price mean-reverts from the oversold reading and advances toward the analyst consensus target as technical conditions normalize.

CounterShort interest of 10% and a put/call ratio of 2.44 indicate substantial bearish positioning that can overwhelm technical oversold signals, keeping the stock depressed even while the longer-term trend remains intact.

Revenue and earnings growth are both running in the low single digits, placing this company near the bottom of its peer group on growth metrics and reducing the likelihood of a meaningful re-rating catalyst.

Stable
Growth
Expectation
Quarterly EPS exceeds $0.40 for 2 consecutive quarters, indicating an acceleration above the current $0.36 run rate.

CounterBest-in-class cash conversion at 288% of net income means that even modest revenue growth generates disproportionate cash flow, which can support distributions and buybacks without requiring rapid top-line expansion.

→ Full pillar scorecard with all 5 pillars + per-dimension breakdown

When this thesis breaks

Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1The business generates free cash flow equal to 288% of net income, posts 64% margins, and holds a perfect Piotroski F-Score of 9/9, placing it among the best-in-class names in its peer group on quality metrics.

    Trip ifFree cash flow as a percentage of net income falls below 150% for 2 consecutive quarters, signaling deterioration in cash conversion quality.

  • P2The company has missed earnings estimates in all four of the most recent reported quarters, with the oldest miss at -15.7% and the most recent narrowing sharply to -1.3%, suggesting analysts are gradually resetting expectations toward actual results.

    Trip ifEPS surprise exceeds 3% for 2 consecutive quarters, confirming the miss streak has reversed.

  • P3RSI is near 20 (oversold), on-balance volume is rising (accumulation), and the stock remains above the 200-day moving average — a combination that creates a potential mean-reversion setup within an intact longer-term uptrend.

    Trip ifPrice falls below the 200-day moving average for 2 consecutive weeks, breaking the longer-term uptrend.

  • P4Analysts see 23% upside to the consensus target from the current price, and recent news sentiment is positive — reflecting research community confidence in the business despite near-term earnings noise.

    Trip ifAnalyst upside to the consensus price target falls below 8% as targets are cut, indicating a meaningful reduction in conviction.

  • P5Revenue and earnings growth are both running in the low single digits, placing this company near the bottom of its peer group on growth metrics and reducing the likelihood of a meaningful re-rating catalyst.

    Trip ifQuarterly EPS exceeds $0.40 for 2 consecutive quarters, indicating acceleration above the current $0.36 run rate.

How the engine reached this verdict

1. Direct answer

TrendMatrix's engine output for CareTrust REIT, Inc. (CTRE) is SELL_IF_HOLDING with medium conviction, score 5.2/10 at $39.43. The F-path SELL output reflects an overall score of 5.2 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of 0.02 is supplementary context, not the trigger.

2. Entry, target, and stop

The engine's exit framework anchors to a tactical sell band near $39.43, with structural invalidation at $37.29. The asymmetric R:R against a reversal hypothesis is 0.04 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).

3. What the engine sees

On the bull side: High-quality business. On the bear side: Analyst target reached - limited upside remaining; Consecutive earnings misses (4); Expensive valuation. Active engine warnings: V8: Target reached (0.2% upside), V9 Gate Failed: ASYMMETRY:0.0<1.5@spot.

4. What would change the verdict

The dominant failed gate is reward-to-risk at 0.0 vs threshold 1.5. SELL flips back toward HOLD if reward-to-risk recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is MOMENTUM:6.8>=5.5.

For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates CTRE — 10-dimension breakdown →

Bull case

  • High-quality business

Bear case

  • Analyst target reached - limited upside remaining
  • Consecutive earnings misses (4)
  • Expensive valuation
Home Stocks CTRE Buy or sell?